AVBP vs AZN
AVBP: Arrivent Biopharma is a clinical-stage oncology company advancing firmonertinib, an EGFR-targeted tyrosine kinase inhibitor for treating non-small cell lung cancer with uncommon mutations, toward pivotal Phase 3 approval. AZN: Leading global biopharmaceutical company developing targeted oncology, cardiovascular, and rare disease treatments backed by a strong R&D pipeline.
Side-by-side fundamentals
| Metric | AVBP | AZN | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $30.44 | $169.73 | |
| Market cap as of 2026-07-23 | $1.3B | $193.7B | |
| P/E as of 2026-07-23 | n/a | 24.93 | |
| PEG as of 2026-07-23 | n/a | 2.64 | |
| Net margin as of 2026-07-23 | n/a | +17.2% | |
| Gross margin as of 2026-07-23 | n/a | +81.4% | |
| Operating margin as of 2026-07-23 | n/a | +23.7% | |
| ROE as of 2026-07-23 | -49.0% | +22.3% | AZN higher |
| ROA as of 2026-07-23 | -45.4% | +9.1% | AZN higher |
| Debt / equity as of 2026-07-23 | 0.00 | 0.72 | AVBP lower |
| Revenue growth (YoY) as of 2026-07-23 | n/a | +9.9% | |
| Dividend yield as of 2026-07-23 | n/a | +1.9% | |
| Beta as of 2026-07-23 | 1.44 | 1.38 | |
| 1-year return as of 2026-07-22 close | +31.1% | +17.0% | AVBP higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.